BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17145584)

  • 1. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
    Mounier N; Vignot S; Spano JP
    Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temsirolimus for the treatment of mantle cell lymphoma.
    Hess G
    Expert Rev Hematol; 2009 Dec; 2(6):631-40. PubMed ID: 21082954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
    Hess G; Smith SM; Berkenblit A; Coiffier B
    Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
    Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
    J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ; Hsu A
    Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
    Yazbeck VY; Buglio D; Georgakis GV; Li Y; Iwado E; Romaguera JE; Kondo S; Younes A
    Exp Hematol; 2008 Apr; 36(4):443-50. PubMed ID: 18343280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma.
    Costa LJ
    Cancer Treat Rev; 2007 Feb; 33(1):78-84. PubMed ID: 17161912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.
    Ekshyyan O; Mills GM; Lian T; Amirghahari N; Rong X; Lowery-Nordberg M; Abreo F; Veillon DM; Caldito G; Speicher L; Glass J; Nathan CO
    Head Neck; 2010 Dec; 32(12):1619-28. PubMed ID: 20222045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
    Shuuin T; Karashima H
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
    Chan S; Scheulen ME; Johnston S; Mross K; Cardoso F; Dittrich C; Eiermann W; Hess D; Morant R; Semiglazov V; Borner M; Salzberg M; Ostapenko V; Illiger HJ; Behringer D; Bardy-Bouxin N; Boni J; Kong S; Cincotta M; Moore L
    J Clin Oncol; 2005 Aug; 23(23):5314-22. PubMed ID: 15955899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.
    Boni JP; Hug B; Leister C; Sonnichsen D
    Semin Oncol; 2009 Dec; 36 Suppl 3():S18-25. PubMed ID: 19963096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antihormonal therapy in breast cancer and mTOR inhibitors].
    Heudel PÉ; Tredan O; Ray-Coquard I; Treilleux I; Guastalla JP; Bachelot T
    Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
    Witzig TE; Geyer SM; Ghobrial I; Inwards DJ; Fonseca R; Kurtin P; Ansell SM; Luyun R; Flynn PJ; Morton RF; Dakhil SR; Gross H; Kaufmann SH
    J Clin Oncol; 2005 Aug; 23(23):5347-56. PubMed ID: 15983389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temsirolimus (Torisel) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
    [No Abstract]   [Full Text] [Related]  

  • 16. Temsirolimus for metastatic desmoplastic small round cell tumor.
    Thijs AM; van der Graaf WT; van Herpen CM
    Pediatr Blood Cancer; 2010 Dec; 55(7):1431-2. PubMed ID: 20730888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
    Bukowski RM
    Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
    Dancey JE; Curiel R; Purvis J
    Semin Oncol; 2009 Dec; 36 Suppl 3():S46-58. PubMed ID: 19963100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mTOR in mantle cell lymphoma: current and future directions.
    Smith SM
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):175-83. PubMed ID: 22687453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
    De Masson A; Fouchard N; Méry-Bossard L; Dauendorffer JN
    Dermatology; 2011; 223(1):4-8. PubMed ID: 21846963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.